The Irish Times
Growth in native pharma depends on nurturing a vibrant start-up ecosystem
Ireland’s burgeoning pharmaceutical start-up scene is gaining global attention, driven by a robust ecosystem of academic-industry partnerships, government support, and a focus on emerging therapeutic areas. Prof. Steve Kerrigan, co-founder of Inthelia Therapeutics, exemplifies this innovation. His team’s breakthrough in host-targeted therapies for sepsis addresses a critical global health challenge. However, as Kerrigan notes, transitioning from research to clinical application presents significant hurdles, including securing funding, navigating regulatory landscapes, and establishing trust with healthcare providers. Discover how Inthelia is navigating these challenges and what it reveals about the broader landscape of biotech entrepreneurship in Ireland.
Read More
